# Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

> **NCT01553149** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 75 (actual)

## Conditions studied

- Neurofibromatosis Type 1
- Recurrent Childhood Pilocytic Astrocytoma
- Recurrent Childhood Visual Pathway Glioma

## Interventions

- **DRUG:** Lenalidomide
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01553149
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-05
- **Primary completion:** 2020-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553149, "Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01553149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*